SC
NRIX icon

Steven Cohen’s Nurix Therapeutics NRIX Stock Holding History

Steven Cohen’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
73,069
-376,037
-84% -$6.41M ﹤0.01% 2470
2026
Q1 		$6.96M Sell
449,106
-2,762,574
-86% -$45.8M 0.01% 1476
2025
Q4 		$60.9M Buy
3,211,680
+340,183
+12% +$4.89M 0.07% 329
2025
Q3 		$26.5M Sell
2,871,497
-832,097
-22% -$8.64M 0.04% 455
2025
Q2 		$42.2M Buy
3,703,594
+3,485,141
+1,595% +$37.7M 0.08% 280
2025
Q1 		$2.6M Sell
218,453
-654,506
-75% -$10.9M 0.01% 1163
2024
Q4 		$16.4M Buy
+872,959
New +$20M 0.04% 525
2024
Q2 		– Sell
-9,500
Closed -$140K – 2274
2024
Q1 		$140K Buy
+9,500
New +$102K ﹤0.01% 1960
2023
Q4 		– Sell
-1,114
Closed -$8.76K – 2602
2023
Q3 		$8.76K Buy
1,114
+1,107
+15,814% +$10.1K ﹤0.01% 2341
2023
Q2 		$67 Sell
7
-9,594
-100% -$97.8K ﹤0.01% 2072
2023
Q1 		$85.3K Buy
+9,601
New +$100K ﹤0.01% 1662
2022
Q2 		– Sell
-69,850
Closed -$979K – 1559
2022
Q1 		$979K Sell
69,850
-66,700
-49% -$1.18M ﹤0.01% 964
2021
Q4 		$3.95M Buy
+136,550
New +$4.14M 0.02% 719

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Steven Cohen's NRIX Position: Q2 2026 in Review

Steven Cohen reduced its Nurix Therapeutics (NRIX) stake by 84% in Q2 2026, selling an estimated $6.41M and leaving 73,069 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

Steven Cohen first reported a position in NRIX in Q4 2021 and has held it in 13 quarters since. The position peaked at $60.9M in Q4 2025. 210 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Steven Cohen held 73,069 shares of Nurix Therapeutics worth $1.77M as of Q2 2026.
  • Steven Cohen sold 376,037 Nurix Therapeutics shares in Q2 2026, an estimated $6.41M.
  • Nurix Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2470 holding.
  • Steven Cohen first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Steven Cohen's Nurix Therapeutics position peaked at $60.9M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.